Lead by example, it helps coalesce a team and team spirit.
Prof. Niederman’s interests lie in respiratory tract infections, including mechanisms of airway colonization, management of community- and hospital-acquired pneumonia, the role of guidelines for pneumonia, and the impact of antibiotic resistance on the management and outcomes of respiratory tract infections. He has published over 400 peer reviewed or review articles, and lectured widely. Dr Niederman served as co-chairman of the committees that created the American Thoracic Society 1993 and 2001 guidelines for the treatment of community-acquired pneumonia and the 1996 and 2005 committees that wrote guidelines for the treatment of nosocomial pneumonia. He was a member of the ATS/IDSA committee that published guidelines for community-acquired pneumonia in 2007. He is Editor-in-Chief of Clinical Pulmonary Medicine, and serves on the editorial boards of Critical Care Medicine, Intensive Care Medicine , Critical Care and Chest. Prior to his appointment at Weill Cornell he was Professor in the Dept. of Medicine at the State University of New York at Stony Brook, and Chairman of the Department of Medicine at Winthrop-University Hospital in Mineola, New York for 16 years. (3/2016)
Please log into your account to view faculty contact details.
Clinical Director, Pulmonary and Critical Care New York Presbyterian-Weill Cornell Medical Center (2015-)
Professor of Clinical Medicine Weill Cornell Medical College (2015-)
Emerging evidence highlights the potential advantages of employing anti-inflammatory therapies like macrolide antibiotics and corticosteroids in managing severe community-acquired pneumonia (CAP). Although their use remains a subject of debate, recent findings indicate improved clinical outcomes, and support the adoption of a tailored approach that emphasises personalised medicine strategies...
READ MOREThis article describes the application of existing and emerging biomarkers in the diagnosis and management of sepsis and pneumonia. Introduction: The Need for Biomarkers in Sepsis Sepsis is defined as a dysregulated host response to infection that results in life threatening organ dysfunction. It carries an estimated 30-day mortality rate of 24.4% and increases to 3
READ MOREBiomarkers are quantifiable indicators of physiological or pathological processes in the body. They can be more effectively utilised in intensive care by improving standardised protocols for biomarker testing and interpretation. Join our panellists as they discuss the use of Biomarkers in critical care and where and how biomarkers can provide valuable diagnostic, prognostic and therapeutic value. ...
READ MOREICU sepsis is associated with a mortality rate >25%, with nosocomial infection most lethal, and community acquired infection more common. Optimal management requires identification of the site of infection (lung, abdomen and blood stream most commonly), a focus on the likely pathogens based on risk factors for resistance, and provision of timely and accurate therapy in the context of appropriate...
READ MORE
Michael S. Niederman, MD, MACP, FCCP, FCCM, FERS is Clinical Director, Pulmonary and Critical Care at New York Presbyterian-Weill Cornell Medical Cente r and Professor of Clinical Medicine at Weill...
READ MOREMichael S. Niederman, MD Professor and Vice-Chairman, Department of Medicine SUNY at Stony Brook Chairman, Department of Medicine Winthrop University Hospital Mineola, New York [email protected] Sepsis bundles are a prescriptive approach to patient management that include a number of superfluous elements, and yet omit important interventions that can improve patient...
READ MOREMichael S. Niederman, MD Professor of Medicine SUNY at Stony Brook Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Introduction Inhaled antibiotics have been available for use in patients with a wide range of respiratory infections, but their role in mechanically ventilated patients has not been routine, and has been primarily as adjunctive...
READ MORE
